GlassScriptPhysician profile
Elyse Spencer
NPI 1740243096
$6,675.86
in general payments reported to CMS, 2019-2025
24 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,114 · 2022: $1,040 · 2023: $1,366 · 2024: $1,359 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,297 · Education: $188 · Travel and Lodging: $36.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,297.03 |
| Education | $188.44 |
| Travel and Lodging | $36.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,059.43 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $988.99 | 2021-2025 | |
| Janssen Biotech, INC. | $681.04 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $414.86 | 2021-2025 | |
| Genzyme Corporation | $377.43 | 2021-2025 | |
| Pfizer INC. | $345.00 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $288.45 | 2021-2024 | Libtayo, Dupixent |
| Incyte Corporation | $285.15 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $261.28 | 2021-2025 | Arazlo, Jublia, Siliq |
| Amgen INC. | $253.59 | 2021-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $219.45 | 2021-2025 | |
| Galderma Laboratories, L.P. | $201.58 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Lilly USA, LLC | $183.58 | 2021-2023 | Taltz |
| Journey Medical Corporation | $163.40 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $148.79 | 2023-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $132.50 | 2021-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $126.01 | 2024-2025 | Adbry, Anzupgo |
| Ucb, INC. | $115.55 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $113.02 | 2023-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $111.09 | 2021 | |
| Botanix Sb INC | $72.87 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $60.20 | 2024 | Vtama |
| Biofrontera INC. | $41.12 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermira, INC. | $31.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyse Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.